Noven gets FDA green light for Secuado

Noven Pharmaceuticals has received the Food and Drug Administration’s blessing for Secuado (asenapine) transdermal system, the first-and-only transdermal patch formulation for the treatment of adults with schizophrenia.

The once-daily transdermal drug delivery system provides sustained concentrations during wear time (24 hours) of the atypical antipsychotic drug asenapine, a well-established treatment for schizophrenia. A transdermal patch may help to mitigate some of the challenges patients face with the management of their schizophrenia, according to the company.

“There is an enormous unmet need for new types of schizophrenia treatments, and Noven is committed to giving people living with this devastating disease and their family members new options that may help them effectively manage their symptoms,” Noven chairman and CEO Naruhito Higo said. “We commend the FDA on the approval of Secuado and look forward to bringing it to market in the United States as soon as possible so people living with schizophrenia have a transdermal delivery option for asenapine treatment.”